The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy
- PMID: 17141973
- PMCID: PMC2001308
- DOI: 10.1016/j.ijrobp.2006.09.021
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy
Abstract
Purpose: A common side effect experienced by head and neck cancer patients after radiation therapy (RT) is impairment of the parotid glands' ability to produce saliva. Our purpose is to investigate the relationship between radiation dose and saliva changes in the 2 years after treatment.
Methods and materials: The study population includes 142 patients treated with conformal or intensity-modulated radiotherapy. Saliva flow rates from 266 parotid glands are measured before and 1, 3, 6, 12, 18, and 24 months after treatment. Measurements are collected separately from each gland under both stimulated and unstimulated conditions. Bayesian nonlinear hierarchical models were developed and fit to the data.
Results: Parotids receiving higher radiation produce less saliva. The largest reduction is at 1-3 months after RT followed by gradual recovery. When mean doses are lower (e.g., <25 Gy), the model-predicted average stimulated saliva recovers to pretreatment levels at 12 months and exceeds it at 18 and 24 months. For higher doses (e.g., >30 Gy), the stimulated saliva does not return to original levels after 2 years. Without stimulation, at 24 months, the predicted saliva is 86% of pretreatment levels for 25 Gy and <31% for >40 Gy. We do not find evidence to support that the overproduction of stimulated saliva at 18 and 24 months after low dose in 1 parotid gland is the result of low saliva production from the other parotid gland.
Conclusions: Saliva production is affected significantly by radiation, but with doses <25-30 Gy, recovery is substantial and returns to pretreatment levels 2 years after RT.
Conflict of interest statement
Conflict of Interest Notification: None.
Figures





Similar articles
-
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1055-69. doi: 10.1016/j.ijrobp.2004.12.076. Int J Radiat Oncol Biol Phys. 2005. PMID: 15990009
-
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87. doi: 10.1016/s0360-3016(99)00247-3. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524409
-
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16. doi: 10.1016/s0360-3016(00)01441-3. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240231
-
Dose and volume impact on radiation-induced xerostomia.Rays. 2005 Apr-Jun;30(2):145-8. Rays. 2005. PMID: 16294907 Review.
-
Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.Head Neck. 2016 Apr;38 Suppl 1:E1746-55. doi: 10.1002/hed.24310. Epub 2016 Feb 15. Head Neck. 2016. PMID: 26875880 Review.
Cited by
-
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.Diagnostics (Basel). 2022 Aug 10;12(8):1926. doi: 10.3390/diagnostics12081926. Diagnostics (Basel). 2022. PMID: 36010276 Free PMC article.
-
Organ-sparing radiation therapy for head and neck cancer.Nat Rev Clin Oncol. 2011 Jul 26;8(11):639-48. doi: 10.1038/nrclinonc.2011.106. Nat Rev Clin Oncol. 2011. PMID: 21788974 Review.
-
Hyaluronan and Reactive Oxygen Species Signaling-Novel Cues from the Matrix?Antioxidants (Basel). 2023 Mar 28;12(4):824. doi: 10.3390/antiox12040824. Antioxidants (Basel). 2023. PMID: 37107200 Free PMC article. Review.
-
Dosimetry of Submandibular Glands on Xerostomia for Nasopharyngeal Carcinoma.Front Oncol. 2021 Jan 11;10:601403. doi: 10.3389/fonc.2020.601403. eCollection 2020. Front Oncol. 2021. PMID: 33505916 Free PMC article.
-
Salivary Gland Volume Changes and Dry Mouth Symptom Following Definitive Radiation Therapy in Oropharyngeal Cancer Patients-A Comparison of Two Different Approaches: Intensity-Modulated Radiation Therapy Versus Intensity-Modulated Radiation Therapy/Intensity-Modulated Proton Therapy Combination.Cancers (Basel). 2025 Feb 6;17(3):554. doi: 10.3390/cancers17030554. Cancers (Basel). 2025. PMID: 39941919 Free PMC article.
References
-
- Cooper JS, Fu K, Marks J, et al. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995;31:1141–1164. - PubMed
-
- Ship JA, Eisbruch A, D'Hondt E, et al. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: 1 year results. J Dent Res. 1997;76:807–813. - PubMed
-
- Jones RE, Takeuchi T, Eisbruch A, et al. Ipsilateral parotid sparing study in head and neck cancer patients receiving radiation therapy: 1 year results. Oral Surg Oral Med Oral Path Oral Radiol Endo. 1996;81:642–648. - PubMed
-
- Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Rad Oncol Biol Phys. 1996;36:469–480. - PubMed
-
- Eisbruch A, Marsh LH, Martel MK, et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Int J Rad Oncol Biol Phys. 1998;41:559–568. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical